MedPath

The trial assesses the efficacy of continuous epidural infusion of ropivacaine 0.125% and 0.2% mixed with fentanyl for prenatal patients undergoing active labour pain management.

Phase 2
Conditions
Health Condition 1: -
Registration Number
CTRI/2024/07/070837
Lead Sponsor
Priti Mourya
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Singleton pregnancy at term (=37 weeks of

gestation) with vertex presentation.

2. Maternal age should be between 19 and 35 years.

Because according to child marriage act the age

of marriage for girls is 18 years and age =35

years is very advanced maternal age with

complicated outcomes like stillbirth, preterm

birth, perinatal death, GDM, gestational

hypertension and preeclampsia.

3. Informed consent provided by the participant.

4. Desire for epidural analgesia for pain

management.

5. Ability to understand and comply with the study

procedures.

Exclusion Criteria

1. Refusal to provide informed consent.

2. Twin pregnancy.

3. Breech presentation.

4. Pregnancy with antepartum haemorrhage.

5. History of adverse reactions to local

anaesthetics or opioids.

6.Medical contraindications to epidural

analgesia like increased intracranial pressure,

local infection at the site of puncture,

haemorrhagic diathesis or

therapeutic anticoagulants.

8. Known foetal anomalies or distress

necessitating

immediate delivery.

9. History of drug abuse.

10. Bleeding disorders.

11. Decreased platelet counts.

12. Spinal column deformities.

13. History of spine surgery.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pain Relief Efficacy: The primary outcome will assess the effectiveness of the analgesic regimens by comparing the degree of pain relief achieved by labouring mothers in Group A (Ropivacaine 0.125% with Fentanyl) and Group B (Ropivacaine 0.2% with Fentanyl). Pain relief will be evaluated using a visual analogue scale (VAS) or other standardized pain assessment tools.Timepoint: 24 months
Secondary Outcome Measures
NameTimeMethod
1.Analgesic Consumption: The total amount of analgesic agents used by participants in each group will be recorded, including the volume of ropivacaine and the amount of fentanyl administered. <br/ ><br>2.Onset and Duration of Pain Relief: The time taken for pain relief to begin (onset) and the duration of effective pain relief for each analgesic regimen will be documented. <br/ ><br>3.Safety and Adverse Events: Adverse events associated with each analgesic regimen, such as hypotension, respiratory depression, or other complications, will be monitored and recorded. <br/ ><br>4.Neonatal Outcomes: The study will assess the impact of the analgesic regimens on neonatal outcomes, including Apgar scores and any immediate interventions required. <br/ ><br>5.Obstetric Outcomes: The effect of pain management choices on obstetric parameters will be analysed. This includes assessing progression, mode of delivery, and any interventions required during. <br/ ><br>Timepoint: 24 months
© Copyright 2025. All Rights Reserved by MedPath